Relmada Therapeutics, Inc.
RLMD
$7.49
$0.040.54%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 94.89% | -15.01% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 96.89% | 1.04% | |||
| Operating Income | -96.89% | -1.04% | |||
| Income Before Tax | -96.88% | -2.28% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -96.88% | -2.28% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -96.88% | -2.28% | |||
| EBIT | -96.89% | -1.04% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -6.97% | -2.25% | |||
| Normalized Basic EPS | -7.48% | -1.82% | |||
| EPS Diluted | -6.97% | -2.25% | |||
| Normalized Diluted EPS | -7.48% | -1.82% | |||
| Average Basic Shares Outstanding | 84.07% | 0.00% | |||
| Average Diluted Shares Outstanding | 84.07% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||